Major depressive disorder and bipolar disorder are severe mood disorders that affect the lives and functioning of millions each year. The majority of previous neurobiological research and standard pharmacotherapy regimens have approached these illnesses as purely neurochemical disorders, with particular focus on the monoaminergic neurotransmitter systems. Not altogether surprisingly, these treatments are inadequate for many individuals afflicted with these devastating illnesses. Recent advances in functional brain imaging have identified critical neural circuits involving the amygdala and other limbic structures, prefrontal cortical regions, thalamus, and basal ganglia that modulate emotional behavior and are disturbed in primary and secondary mood disorders. Growing evidence suggests that mechanisms of neural plasticity and cellular resilience, including impairments of neurotrophic signaling cascades as well as altered glutamatergic and glucocorticoid signaling, underlie the dysregulation in these circuits. The increasing ability to monitor and modulate activity in these circuits is beginning to yield greater insight into the neurobiological basis of mood disorders. Modulation of dysregulated activity in these affective circuits via pharmacological agents that enhance neuronal resilience and plasticity, and possibly via emerging nonpharmacologic, circuitry-based modalities (for example, deep brain stimulation, magnetic stimulation, or vagus nerve stimulation) offers promising targets for novel experimental therapeutics in the treatment of mood disorders.
INTRODUCTION
Major depressive disorder (MDD) and bipolar disorder (BD), two of the most severely debilitating medical illnesses, 1 affect the lives and functioning of millions worldwide. MDD and BD have historically been conceptualized as episodic illnesses with full recovery between episodes. However, a growing number of studies indicate that, for a significant number of patients, outcome is quite poor, with high rates of relapse, chronicity, lingering residual symptoms, subsyndromes, cognitive and functional impairment, psychosocial disability, and diminished well-being. [2] [3] [4] [5] Suicide is estimated to be the cause of death in up to 15% of individuals with mood disorders. In addition to this serious health risk, systemic manifestations of other medical conditions commonly co-occur in patients with a mood disorder. 6 -9 Despite the clinical impact of these disorders on patient's lives, their families and the community, the current understanding of the precise neurobiological underpinnings of MDD and BD is limited. Historically, the focus in neurobiologic studies of mood disorders has been the monoaminergic neurotransmitter systems, which are extensively distributed throughout the network of limbic, striatal, and prefrontal cortical neuronal circuits thought to support the behavioral and visceral manifestations of mood disorders. 10, 11 Whereas these neurotransmitter systems undoubtedly play an important role in modulating the expression of certain signs/symptoms of mood disorders, the currently approved treatments that primarily target these systems have a number of drawbacks including delayed clinical response/remission (weeks to months) and, too frequently, incomplete or absent response/remission.
Clearly, there is a great clinical need for the ongoing development of new therapies that are more effective, rapid-acting, and easily tolerated than existing therapies.
In this review, we discuss the prospect of developing new treatments for mood disorders based upon two approaches:
1) Understanding the nature of critical neural circuits that are dysregulated in individuals with mood disorders, and using this knowledge to develop strategies to directly manipulate activity in these circuits.
2) Understanding the disturbances of neural plasticity and cellular resilience that seem to underlie aberrant activity in these circuits, and targeting therapeutics to attenuate or prevent these pathological processes.
1) NEURAL CIRCUITRY IN MOOD DISORDERS: IMPLICATIONS FOR EXPERIMENTAL THERAPEUTICS
A greater understanding of the neural circuits underlying mood in both normal and abnormal affective states has been identified as one of the critical needs in the field of mood disorders research. 11 The early yet significant advances made in this area in recent years are beginning to provide a neuroanatomical framework in which to better understand mechanisms of current treatment modalities and guide efforts for the development of novel therapeutics. The following sections summarize a variety of neuroanatomic findings that hold potential therapeutic implications for mood disorders.
Functional anatomy of mood disorders
Functional imaging studies of mood disorders have identified key brain regions involved in a network of limbic, striatal, and prefrontal cortical circuits thought to support the behavioral, cognitive, and visceral manifestations of mood disorders. 10 -13 Key brain regions that have shown consistent abnormalities in mood disorders are discussed below ( see FIG. 1 ).
The amygdala. Resting cerebral blood flow (CBF) and glucose (GLC) metabolism in the amygdala have consistently been demonstrated to be elevated in individuals with primary mood disorder subtypes including familial pure depressive disorder (FPDD) 14 and nonpsychotic BD. [15] [16] [17] [18] Although abnormal amygdalar activation during task performance has been noted in many other psychiatric disorders, this abnormality of resting CBF and metabolism may be specific to certain forms of primary mood disorder. 19 Furthermore, amygdalar activity as measured by CBF and GLC metabolism has been shown to correlate positively with both depression severity 16, 17, 20 and susceptibility to depressive relapse. 21 A number of studies have demonstrated increased amygdalar responses in activation paradigms for those with mood disorders. [22] [23] [24] Interestingly, it has recently been reported that healthy carriers of the short (s) allele of the functional promoter polymorphism for the serotonin transporter gene (a finding that confers increased risk of depression) exhibit amygdalar hyperactivity. [25] [26] [27] One significant function of the amygdala is to evaluate the emotional valence-be it positive 28 or negative 29 -31 -of an experience. The amygdala also plays a key role in the acquisition and expression of emotionally charged memories as well as the emotional interpretation of social cues (reviewed by Drevets 12 ). Thus, amygdalar dysregulation may have a direct phenomenological link with the emotionally biased interpretations of past, present, and future events and interactions frequently experienced in mood disorders. Extensive amygdalar projections to the hypothalamus and various brainstem nuclei may mediate many of the autonomic and somatic manifestations, social withdrawal, and fearful/defensive behaviors associated with depression (reviewed in Drevets 2001 ).
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The orbital cortex. Several studies have reported abnormally increased CBF/metabolism bilaterally in the posterior orbital cortex as well as in the left ventrolateral prefrontal cortex (VLPFC) and the anterior insula in unmedicated subjects with primary MDD. 16, 17, [32] [33] [34] [35] This finding is not specific for mood disorders, as it has been reported in various anxiety disorders as well as in experimentally induced sadness and anxiety. 36 Although CBF/ metabolism seems to consistently be decreased in the remitted phase as compared with the depressed phase of MDD, 17, [37] [38] [39] an inverse relationship between depression severity and CBF/metabolism during the depressed phase of the illness has been reported. 16, 17 Studies of relatively mild, treatment-responsive depression in subjects with MDD or BD have shown increased orbital activity relative to healthy controls, whereas more severely depressed, treatment-resistant individuals with MDD or BD, as well as individuals with depression secondary to neurological disorders, showed no difference or had decreased activity of this region relative to controls. 12 Based on these observations, increased orbital CBF and metabolism in depression seems to be an endogenous compensatory mechanism. The orbital cortex and amygdala modulate each other's actions through direct reciprocal connections as well as through overlapping projections to the periaqueductal gray, hypothalamus, and striatum. 40 -42 Pyramidal cells from the orbital cortex are implicated in extinction of unreinforced responses to both rewarding and aversive stimuli. [43] [44] [45] Humans and nonhuman primates with lesions of the orbital cortex perseverate in unreinforced behavioral responses and have difficulty switching intellectual strategies as reinforcement contingencies evolve. 44,46 -49 Thus, dysfunction of the orbital cortex and VLPFC may predispose individuals to the perseverative cognitions and emotional responses characteristic of depression.
The subgenual anterior cingulate. Metabolism and CBF of the subgenual anterior cingulate cortex (ACC) have repeatedly been measured to be decreased in unipolar and bipolar depression relative to control samples. 50 -52 Interestingly, CBF and metabolism in this region were reported to decrease further with successful antidepressant treatment. 38, 50, 51 This observation was clarified by the finding of a left-lateralized volumetric reduction of the subgenual ACC in depressed subjects versus controls. 51, 53 In computer simulations that correct positron emission tomography (PET) data for the partial volume effect of gray matter volume reductions, the corrected subgenual metabolic activity in depressed subjects was increased relative to controls, 54 and this hypermetabolism returned to normal levels with effective treatment. 55 Even when uncorrected for partial volume averaging effects, subgenual ACC metabolism appears abnormally increased in manic subjects. 12 Evidence from lesion studies in rats suggests that leftsided lesions of the subgenual PFC are associated with increased corticosterone secretion and sympathetic autonomic arousal in response to stress, whereas right-sided subgenual lesions had the opposite effect. 12 Through its efferent projections to the ventral tegmental area (VTA) that act to increase dopamine (DA) release in the ventral striatum, the subgenual PFC also appears to play a role in evaluating the reward-related salience of stimuli. 12, 54 Thus, disturbances in this region may relate to disruptions in hedonic tone and motivation seen in depression and mania.
The dorsomedial prefrontal cortex. Based on studies of anticipated electrical shock in healthy human subjects, preclinical lesion models, and functional connectivity, the dorsomedial (DM) and dorsal anterolateral (DAL) PFC are thought to attenuate anxiety, defensive behavior, and cardiovascular responses to stress. 42, 56, 57 Several PET studies have shown abnormally decreased CBF and metabolism in these regions in individuals with primary depression as well as in depressed subjects with Parkinson's disease. 54,58 -60 The dorsolateral prefrontal cortex and dorsal anterior cingulate cortex. Multiple regions of the dorsolateral PFC (DLPFC) and dorsal ACC are activated in cognitive tasks related to working memory and attention. 35 These regions show abnormal reductions in CBF and metabolism during depression 54, 61 and normalize during symptom remission. 38, 62 Drevets and Raichle 36 hypothesize that activity in these cognitive circuits may be suppressed as a natural response to increased emotional processing. Although the altered activity in the DLPFC and dorsal ACC may not be centrally involved in the circuitry of mood disorders, it could account for some of the subtle disturbances of attention, memory, and visuospatial function manifested in these illnesses. 63 Alternatively, a recent functional imaging study involving a social challenge paradigm found that healthy control subjects activated the DLPFC in response to hearing critical remarks, whereas fully remitted MDD subjects failed to activate this area. 64 The possibility remains that a subtle trait-related dysfunction in the DLPFC could predispose to depression in at least a subset of those with mood disorders.
The mediodorsal thalamus. Depressed MDD and BD subjects manifest abnormal increases of metabolism and CBF in the left mediodorsal nucleus of the thalamus (MD). 16, [65] [66] [67] This nucleus has extensive connections with the amygdala as well as the orbital cortex, VLPFC, and subgenual PFC. The ventral striatum. The ventral striatum also has been noted to have extensive connections with the amygdala and the orbital, subgenual, and ventrolateral PFC. 43 As mentioned above, it is also a key target of dopaminergic projections from the VTA. This VTA-accumbens circuit is a critical reward pathway of the brain. The relationship of this pathway to mood disorders requires further study, but it seems plausible that disturbances in this pathway would be related to abnormalities in hedonic tone and motivation, 11 which are central features of mania and depression. This is supported by the finding of decreased striatal response to happy stimuli associated with level of anhedonia in depressed subjects 68 as well as the observation of increased striatal activity in mania, 69 a state characterized by hedonic excess.
Volumetric studies in mood disorders
Differences have not been detected between MDD and BD subjects and healthy controls in whole brain volume as well as in the volume of the PFC as a whole and many other brain regions. 18, 70 However, morphometric magnetic resonance imaging studies report a decrease in the gray matter volume of specific key areas of the orbital cortex, MPFC, DLPFC, mesial temporal lobe, and basal ganglia [71] [72] [73] [74] [75] ( see FIG. 1 ). As mentioned above, the most prominent reduction is reported in the left (but not right) subgenual prefrontal cortex. An increase in the size of the third ventricle also has been consistently reported in patients with bipolar disorder, suggesting volumetric re-duction of the thalamus and hypothalamus (reviewed in Beyer et al., 2004; 76 Manji et al., 2003 77 ). These volumetric changes may appear early in the course of illness. Dickstein et al. (2005) 76 noted reductions in the left DLPFC and, to a lesser extent, in the left accumbens and left amygdala among a group of 20 BD subjects. Amygdalar volume reduction has been reported in a group of 20 children and adolescents with MDD (Rosso et al., 2005) . 77 This finding could possibly precede symptom onset because decreased gray matter of the amygdala and perigenual cingulate has also been reported in short allele carriers for the functional promoter polymorphism of the serotonin transporter gene. 26 
Histopathological studies in mood disorders
Guided by these functional and structural imaging findings, postmortem histopathological studies have shown abnormal reductions in cortex volume, glial cell counts, and/or neuron size in the subgenual PFC, orbital cortex, dorsal anterolateral PFC, amygdala and in basal ganglia and dorsal raphe nuclei 78 -80 ( see FIG. 2 ). It is not known whether these deficits constitute developmental abnormalities that may confer vulnerability to abnormal mood episodes, compensatory changes to other pathogenic processes, or the sequelae of recurrent mood episodes per se. This marked reduction in glial cells is particularly intriguing in light of growing appreciation of the critical role played by glia in modulating neuronal synaptic neurotransmission, plasticity, and regeneration and contributing to various pathological processes that impair brain function. [81] [82] [83] [84] [85] [86] Abnormalities of glial function could thus prove integral to the impairments of structural plasticity and overall pathophysiology of mood disorders.
Presumptive mood disorder circuits
These findings have led to the identification of two critical circuits involved in mood disorders. 10, 12, 16 The first of these, the limbic-thalamic-cortical (LTC) circuit, comprises the amygdala, the mediodorsal thalamus, and the orbital and medial PFC. These regions are all interconnected by excitatory glutamatergic projections. 43 A second circuit, the limbic-cortical-striatal-pallidal-thalamic (LCSPT) circuit, includes the components of the LTC circuit as well as related areas of the striatum and pallidum 87 ( see FIG. 1 ). A number of more recent studies also support the involvement of these regions and circuits. 67,88 -96 In both of these circuits, pathologically increased amygdalar activity drives increased activity in the PFC and medial thalamus.
The involvement of these circuits in mood disorders is supported not only by imaging findings in primary mood disorders, but also by the increased frequency of mood disturbance in various neurological conditions (e.g., Huntington's and Parkinson's diseases, strokes, and tumors) that involve lesions in these areas. [97] [98] [99] Conversely, surgeries such as subcaudate tractotomy, prefrontal/limbic leukectomy, and anterior cingulotomy that have been used to alleviate intractable depression affect these circuits by disrupting projections from the amygdala to the ACC or the striatum.
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Effects of current and experimental treatments in modulating affective circuits Effective treatment with antidepressant medication has been associated with modulation of activity in the circuits described above. [107] [108] [109] A number of studies have demonstrated that effective treatment with antidepressant medication consistently decreases CBF and metabolism in the amygdala and orbital/insular cortex. 59 Decreasing amygdalar hyperactivity may be a primary effect of these medications, which would then allow the orbital cortex to "relax." 12 The effects on neural circuitry of various antidepressant medications as well as other forms of proven or potential antidepressant treatment are reviewed in Table 1 .
The dopamine agonist pramipexole is the only treatment for which there are two positive controlled trials in acute bipolar depression.
110,111 PET 18 F-fluorodeoxyglucose scans of cerebral glucose metabolism were acquired in 15 subjects with bipolar II depression (BD II) at baseline and at the end of a 6-week double-blind, placebocontrolled add-on clinical trial of pramipexole. Pramipexole treatment reduced metabolic activity in some regions where metabolism was abnormally elevated in the baseline depressed condition, such as the ventrolateral and anteromedial PFC, consistent with the effects of other somatic antidepressant treatments. In contrast to functional imaging studies of conventional antidepressant medications, pramipexole did not alter metabolism in the amygdala but did increase activity in the premotor cortex, hippocampus, posterior cingulate cortex, and superior temporal gyrus. 112 For electroconvulsive therapy (ECT), the most effective acute depression treatment to date, good clinical response is associated with electrode placement over the PFC 113 and with relatively decreased activity after treatment in the PFC, anterior cingulate, and temporal and parietal cortices. 39, 114 Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT), two forms of psychotherapy studied for efficacy in the treatment of depression, have effects on affective circuitry that are distinct from those of antidepressant medication. 37, 115, 116 A "top-down" mechanism has been postulated in which these therapies may enhance function of the orbital cortex/anterior insula and other cortical regions to more effectively attenuate dysregulated limbic activity. 12, 116 These findings support the hypothesis that it is an imbalance within these circuits, rather than any specific directional disturbance in a sin- gle region, that provides a neural substrate for mood dysregulation. Magnetic seizure therapy (MST), an experimental technique using a magnetic field to induce a seizure, is currently being investigated in the treatment of depression by Lisanby et al. 117 They have reported some preliminary evidence that MST may have fewer cognitive side effects than ECT. They further hypothesize that, based on intracerebral electrode studies in nonhuman primates and the fact that magnetic fields are not impeded by skull and soft tissues as is electricity, MST (if proven effective) may represent an improvement over ECT as the seizure can be more directly targeted at affective circuits and therefore may have fewer cognitive side effects than ECT.
Repetitive transcranial magnetic stimulation (rTMS) has been reported to have a variety of effects on activity within affective circuits. 118 Results of clinical trials have been mixed. Whereas some studies have shown antidepressant effects, 118, 119 rTMS remains an investigational technique in the United States. Sapolsky 120 notes that neurogenesis (which has been shown to be induced by antidepressant medications and ECT) is not induced by rTMS. Further research is needed to address various parameters of optimal treatment delivery before the question of clinical efficacy for rTMS can be definitively answered.
Vagus nerve stimulation (VNS), previously approved for treatment of refractory epilepsy, has recently been approved in the United States for use in treatment-resistant mood disorders. A number of functional imaging studies have demonstrated that VNS is associated with altered activity of the thalamus and hypothalamus, amygdala and related limbic structures, orbital cortex, basal ganglia, cerebellum, and medulla. 121, 122 Although initial open trials suggested a substantial acute and long-term benefit in treatment-resistant depression, 123 ,124 a larger randomized controlled trial failed to show acute efficacy. 125 Evidence exists for modest efficacy at long-term (12 months) follow-up. 126, 127 In recent years, chronic deep brain stimulation (DBS) in pathologically overactive neural circuits has been found to produce significant therapeutic benefits in those who suffer from Parkinson's disease. 128, 129 In a preliminary and uncontrolled yet intriguing experiment, Mayberg et al. 130 applied high-frequency DBS to the subgenual cingulate (BA25) of six subjects with severely treatment-refractory depression. All six subjects experienced acute effects intraoperatively including an increased sense of well-being, interest, and calmness as well as an enhanced awareness of the physical surroundings. At months 2 through 4 after implantation, five of the six subjects had a greater than 50% improvement in their depressive symptoms. Four of these subjects maintained this response at 6 months after implantation. Antidepressant response to DBS was associated by CBF decreases in BA25 and adjacent orbital cortex, anterior insula, hypothalamus, and medial frontal cortex (BA10) as well as CBF increases in DLPFC, dorsal anterior and posterior cingulate, premotor, and parietal (BA40) regions (as measured by PET at 3 and 6 months after implantation). As the mechanism of DBS has not been clearly delineated, it remains unclear whether this effect may have resulted from inhibition, stimulation, or disruption of the neural projections traversing and/or emanating from this area. 131 The optimal site for DBS in the treatment of mood disorders remains to be determined. Jimenez et al. 132 describe achieving good antidepressant effect in an individual with refractory MDD using DBS in the inferior thalamic peduncle, presumptively altering activity in thalamo-orbitofrontal pathways. 106 Further advances in the understanding of neural circuitry abnormalities in mood disorders will allow us to refine current treatments and develop novel therapeutic strategies in these illnesses.
2) IMPAIRMENTS OF CELLULAR RESILIENCE AND STRUCTURAL PLASTICITY: POTENTIAL PATHOGENIC MECHANISMS AND THERAPEUTIC TARGETS
The therapeutic strategies discussed above appear to modulate, either directly or indirectly, abnormalities in affective circuits in those who suffer from mood disorders. Elucidation of the factors that originate and/or maintain aberrancy in these circuits will undoubtedly lead to more effective and better tolerated treatment approaches. Converging lines of evidence indicate that impairments of cellular plasticity and resilience may underlie the pathophysiology of mood disorders. 11, [133] [134] [135] [136] Here, we propose that disturbances in neural plasticity and cellular resilience are critical factors in precipitating and perpetuating disruption of the affective circuits discussed above ( see FIG. 2 ). Furthermore, we hypothesize that novel treatment interventions that directly address impairments in plasticity and cellular resilience will both lead to improved clinical outcomes and also show normalization of activity in these circuits. In the remaining sections, we review such potential therapeutic targets.
Stress and glucocorticoids modulate neural plasticity: implications for affective circuits
Although mood disorders undoubtedly have a strong genetic basis, considerable evidence has shown that severe stressors are associated with a substantial increase in risk for the onset of mood disorders in susceptible individuals. 132 Activation of the hypothalamic-pituitaryadrenal (HPA) axis seems to play a role in mediating these effects, as stress-induced neuronal atrophy is prevented by adrenalectomy. 137, 139 These observations are noteworthy with respect to the pathophysiology of major depressive disorders and bipolar disorder as a significant percentage of patients with mood disorders display some form of HPA axis activation, and the subtypes of depression most frequently associated with HPA activation are those most likely to be associated with hippocampal volume reductions. 140, 141 A positive correlation has been reported between left amygdala metabolism and stressed cortisol levels in both MDD and BD depressed subjects. 15 This correlation could reflect either an effect of cortisol on amygdala function or an effect of amygdalar hyperactivity on CRH secretion. Corticosterone injection and exposure to acute and chronic stress have all been shown to disrupt dendritic morphology in the medial PFC. [142] [143] [144] Another significant effect of stress and glucocorticoids is to reduce cellular resilience, rendering certain neurons more vulnerable to other insults such as ischemia, hypoglycemia, and excitatory amino acid toxicity. 134 The precise mechanisms by which glucocorticoids exert these deleterious effects are unclear, but likely involve the facilitation of glutamatergic signaling and inhibition of glucose transport. 145 Decreased resilience of hippocampal neurons may also reflect the propensity for various stressors to decrease the expression of BDNF in this region.
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The role of glutamate in disturbance of affective circuits
Increased activation of NMDA as well as non-NMDA ionotropic glutamate receptors can result in neurotoxicity via overactivation of calcium-dependent enzymes and the generation of oxygen free radicals 134 ( see FIG. 3 ). Substantial evidence suggests that excessive glutamate transmission (which may be precipitated by stress) plays a central role in atrophy of CA3 pyramidal neurons in the hippocampus. Conversely, NMDA antagonists have been found to block hippocampal atrophy. 138, 140 As noted above, the projections in the LTC circuit are predominantly glutamatergic. The consistent overactivity seen in this circuit in mood disorders is likely to be associated with chronically elevated levels of glutamate in these regions. The anatomically selective distribution of neuropil decreases and the loss of glial cells in these areas (which are shown to be the primary uptake mechanism for glutamate from the synapse 146 ) further support the involvement of glutamate toxicity in the disturbance of affective circuitry.
Evidence suggesting that mitochondrial function may play a critical role in the pathophysiology and treatment of BD Although the primary function of mitochondria is to convert organic materials into cellular energy in the form of ATP, mitochondria also play an important role in many important metabolic tasks, such as apoptosis, glutamate-mediated excitotoxic neuronal injury, cellular proliferation, and regulation of the cellular redox state. Mitochondrial diseases can affect any part of the body but are often seen in organs requiring high energy such as the brain, skeletal muscle, and the heart. Kato and Kato 147 had anticipated some of the recent developments in the field when they first proposed that mitochondrial dysfunction may play an important role in the pathophysiology of BD. Since then, there have been a number of human neuroimaging and postmortem brain studies, as well as preclinical molecular and cellular biologic studies that strongly support the argument that mitochondria may play a central role in the impairments of plasticity and cellular resilience manifest in BD. It is not our contention that BD is a classical mitochondrial disorder; thus, the vast majority of BD patients do not show the symptoms of classical mitochondrial disorders such as optic and retinal atrophy, seizures, dementia, ataxia, myopathy, exercise intolerance, cardiac conduction defects, diabetes, lactic acidosis, etc.
Magnetic resonance spectroscopy (MRS) has opened up a wide new avenue into in vivo brain chemistry, thus providing insight into the biochemical pathology of bipolar disorder. Studies using proton ( 1 H) MRS have identified changes in cerebral concentrations of N-acetyl aspartate (NAA), glutamate/glutamine (Glx), cholinecontaining compounds, myo-inositol (mI), and lactate in bipolar subjects compared with normal controls. 148 Studies using phosphorus ( 31 P) MRS have examined additional alterations in levels of phosphocreatine (PCr), phosphomonoesters (PMEs), and intracellular pH (pHi). 149 These seemingly disparate findings of increased lactate and GLX, decreased NAA, and decreased pHi in bipolar subjects suggest a shift away from oxidative phosphorylation toward glycolysis, leading to reduced total energy output and efficiency (reviewed in Stork and Renshaw 2005). 148 Mitochondria play a critical role in maintaining calcium homeostasis. Excessive levels of calcium are a critical mediator of cell death cascades within neurons, necessitating homeostatic mechanisms to regulate intracellular calcium levels precisely. 150 Interestingly, impaired regulation of Ca 2ϩ cascades are among the most reproducible biological abnormalities described in BD research. 151 The diverse findings seen on MRS may be directly related to alterations of calcium response and intracellular signaling systems in bipolar patients.
Most recently, Konradi and associates 152 These cumulative findings of calcium dysregulation, abnormal nuclear mitochondrial gene expression, and shift from oxidative phosphorylation toward glycolysis are highly suggestive of underlying mitochondrial dysfunction in bipolar subjects ( see FIG. 3 ). This has enormous potential for advancing the study of bipolar illness, particularly in terms of treatment. Investigations of mitochondria-based neurological disorders, including Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and mitochondrial cytopathies, is leading to the development of a number of therapies that target cellular energy dysfunction. If mitochondrial dysfunction is involved in the underlying pathology of BD, such therapies may also prove beneficial in the treatment of bipolar disorder. Supplements such as coenzyme q10, carnitine nicotinamide, and lipoic acid have been studied in classical mitochondrial diseases and are worth investigating in BD.
Neurotrophic signaling cascades
Neurotrophins comprise a family of proteins that mediate growth, differentiation, and survival of neurons, as well as the modulation of synaptic transmission and synaptic plasticity. The neurotrophin family now includes NGF, BDNF, neurotrophin-3 (NT-3), NT-4/5, and NT-6. 153, 154 Neurotrophins are initially synthesized as precursors (proneurotrophins), which serve as signaling molecules by interacting with the p75 pan-neurotrophin receptor (p75 NTR ). Proneurotrophins are cleaved to produce mature neurotrophins, which promote neuronal survival and enhance synaptic plasticity by preferentially binding to Trk receptor tyrosine kinases (Trk FL ). There are several subtypes of Trk receptor kinases that are characterized by specific affinity for the different neurotrophins. NGF binds preferentially to TrkA, whereas BDNF and neurotrophin (NT)-4/5 show a high affinity for TrkB. NT-3, on the other hand, predominantly activates TrkC but can also bind to TrkB and TrkA, albeit with lower affinity. Interaction of mature neurotrophins with Trk receptors leads to cell survival, whereas binding of proNGF to p75 NTR leads to apoptosis. 155 The functional importance of the pro region of BDNF was demonstrated in a recent study that investigated the consequences of a single nucleotide polymorphism in this region. This polymorphism is defined by replacement of valine 156 with methionine and is associated with memory deficits and abnormal hippocampal function in humans. 153 Neurotrophins are secreted constitutively or transiently, and often in an activity-dependent manner. Within the neurotrophin family, BDNF is a potent physiological survival factor implicated in a variety of pathophysiological conditions, including mood disorders. BDNF and other neurotrophic factors are necessary for   FIG. 3 . Neuroplasticity and cellular resilience in mood disorders. This figure depicts the multiple influences on neuroplasticity and cellular resilience in mood disorders. Stress and depression likely contribute to impairments of cellular resilience by a variety of mechanisms, including reductions in the levels of BDNF, facilitating glutamatergic transmission via NMDA and non-NMDA receptors, and reducing the cells' energy capacity. Neurotrophic factors such as BDNF enhance cell survival by activating two distinct signaling pathways: the PI-3K pathway, and the ERK-MAP kinase pathway. One of the major mechanisms by which BDNF promotes cell survival is by increasing the expression of the major cytoprotective protein, Bcl-2. The chronic administration of a variety of antidepressants increases the expression of BDNF, and its receptor TrkB. Lithium and VPA robustly upregulate the cytoprotective protein Bcl-2. Lithium and VPA also inhibit GSK-3␤, biochemical effects shown to have neuroprotective effects. VPA also activates the ERK-MAP kinase pathway, effects that may play a major role in neurotrophic effects and neurite outgrowth. BDNF ϭ trkB, tyrosine kinase receptor for BDNF; Bcl-2 and Bcl-x ϭ antiapoptotic members of the Bcl-2 family; BAD and Bax ϭ proapoptotic members of the Bcl-2 family; Ras, Raf, MEK, ERK ϭ components of the ERK-MAP kinase pathway; Rsk-2 ϭ ribosomal S-6 kinase; ROS ϭ reactive oxygen species. Adapted from Charney and Manji 2005.
the survival and function of neurons, implying that a sustained reduction of these factors could affect neuronal viability. 157 However, somewhat less well appreciated is the fact that BDNF also has a number of acute effects on synaptic plasticity and neurotransmitter release, including facilitating the presynaptic release of acetylcholine, glutamate, and GABA. In this context, BDNF has been shown to potentiate both excitatory and inhibitory neuronal transmission, albeit via different mechanisms; BDNF strengthens excitation primarily by enhanced phosphorylation of the NMDA receptors and augmenting the amplitude of AMPA receptor-mediated miniature excitatory postsynaptic current (mEPSCs). 158 It enhances inhibition by increasing the frequency of mI (inhibitory) PSCs and increasing the size of GABAergic synaptic terminals.
It is noteworthy that although endogenous neurotrophic factors have traditionally been viewed as increasing cell survival by providing necessary trophic support, it is now clear that their survival-promoting effects are mediated in large part by an inhibition of cell death cascades. Increasing evidence suggests that neurotrophic factors inhibit cell death cascades by activating the mitogen-activated protein (MAP) kinase signaling pathway and the phosphotidylinositol-3 kinase (PI-3K)/Akt pathway. One important mechanism by which the MAP kinase signaling cascades inhibit cell death is by increasing the expression of the antiapoptotic protein Bcl-2 (B cell lymphoma-2). 157 Accumulating data suggest that not only is Bcl-2 neuroprotective, but it also exerts neurotrophic effects and promotes neurite sprouting, neurite outgrowth, and axonal regeneration. Moreover, a recent study demonstrated that severe stress exacerbates stroke outcome by suppressing Bcl-2 expression. 159 In this study, the stressed mice expressed approximately 70% less Bcl-2 mRNA than unstressed mice after ischemia. Furthermore, stress greatly exacerbated infarct in control mice but not in transgenic mice that constitutively express increased neuronal Bcl-2. Finally, high corticosterone concentrations correlated with larger infarcts in wildtype mice but not in Bcl-2-overexpressing transgenic mice. Thus, enhanced Bcl-2 expression appears to be capable of offsetting the potentially deleterious consequences of stress-induced neuronal endangerment, suggesting that pharmacologically induced upregulation of Bcl-2 may have considerable utility in the treatment of a variety of disorders associated with endogenous or acquired impairments of cellular resilience.
Overall, it is clear that the neurotrophic factors/MAP kinase/Bcl-2 signaling cascade plays a critical role in cell survival in the CNS ( see FIG. 4) , and that there is a fine balance maintained between the levels and activities of cell survival and cell death factors. Modest changes in this signaling cascade or in the levels of the Bcl-2 family of proteins (potentially due to genetic, illness, or insultrelated factors) may therefore profoundly affect cellular viability. We now turn to a discussion of the growing body of data suggesting that neurotrophic signaling molecules play important roles in the treatment of mood disorders.
Antidepressants affect neurotrophic signaling within affective circuits
A number of studies have investigated the possibility that the factors involved in neuronal atrophy and survival could be the target of antidepressant treatments. 160, 161 These studies demonstrate that one pathway involved in cell survival and plasticity, the cAMP response element binding protein (CREB) cascade is upregulated by antidepressant treatment. This group has also demonstrated that antidepressant treatment in vivo increases CREB phosphorylation and CRE-mediated gene expression in mouse limbic brain regions. 162 Upregulation of CREB and BDNF occurs in response to several different classes of antidepressant treatments, indicating that the cAMP-CREB cascade and BDNF are common postreceptor targets of these therapeutic agents.
In addition, upregulation of CREB and BDNF is dependent on chronic treatment over weeks, consistent with the time to onset of therapeutic effects of antidepressants. The importance of neurotrophic signaling in the mechanism of antidepressants is illustrated by findings that induced CREB overexpression in limbic areas 163 as well as BDNF infusion into CA3 of the hippocampus 164 or into the midbrain 165 each produce antidepressant-like effects in animal models of depression. Indirect human evidence comes from studies showing increased hippocampal BDNF expression in postmortem brains of subjects with mood disorders treated with antidepressants at the time of death versus antidepressantuntreated subjects. 166 Chronic administration of an atypical antidepressant, tianeptine, was reported to block the stressinduced atrophy of CA3 pyramidal neurons in adult male rats. 167 Czeh et al. 168 reported that stress-induced changes in brain structure and neurochemistry were counteracted by treatment with tianeptine.
Neurotrophic effects of lithium and divalproex
Lithium and divalproex have emerged as robust neuroprotective agents in preventing apoptosis of neurons. 169, 170 In addition to lithium's effects on a number of intracellular cascades, lithium also induces the expression of BDNF and subsequent activation of TrkB, the receptor for BDNF, in cortical neurons. The activation of BDNF/TrkB signaling is essential for the neuroprotective effects of this drug. In addition, lithium stimulates the proliferation of neuroblasts in primary cultures of CNS neurons. Lithium also shows neuroprotective effects in rodent models of diseases. In a rat model of stroke, postinsult treatment with lithium or valproate at therapeutic doses markedly reduces brain infarction and neurological deficits. This neuroprotection is associated with suppression of caspase-3 activation and induction of chaperone proteins such as heat shock protein 70. In a rat model of Huntington's disease (HD) in which an excitotoxin is unilaterally infused into the striatum, both long-and short-term pretreatment with lithium reduces DNA damage, caspase-3 activation, and loss of striatal neurons. This neuroprotection is associated with upregulation of Bcl-2. 171 Brain imaging studies provide evidence that lithium exerts neurotrophic effects in the human brain in vivo. Proton magnetic resonance spectroscopy has been used to show that total gray-matter content in the human brain of Nacetylaspartate (NAA, a putative marker of neuronal variability and function 172, 173 ) were significantly increased after 4 weeks of lithium treatment. 174 In a longitudinal highresolution volumetric MRI study in well-characterized, medication-free bipolar depressed subjects (Moore et al., submitted), total brain gray matter (GM), prefrontal GM, and left subgenual GM were determined at baseline and after 4 weeks of blinded lithium treatment. 175 Significant increases in total brain GM in bipolar subjects were observed after chronic lithium administration. The regionspecific analyses revealed significant differences between responders (Ͼ50% decrease in HAM-D) and nonresponders; only responders showed increases in GM in the prefrontal cortex and left subgenual prefrontal cortex. The time frame of these effects and their relationship with clinical response suggest that pharmacologic strategies to enhance cellular plasticity and resilience may have utility not only for the long-term course of the illness, but also for treatment of the acute illness.
Sleep deprivation
Sleep deprivation is the only known therapeutic maneuver that appears to alter mood in a majority of both bipolar and unipolar patients in a matter of hours. Sleep deprivation is also capable of triggering switches into mania/hypomania, and therefore the study of the potential cellular mechanisms by which sleep deprivation may bring about these rapid behavioral changes in patients with mood disorders may be particularly informative. There is now incontrovertible evidence that the expression of selected critical genes varies dramatically during sleep and waking events, which likely plays a major role in regulating various and long-term neuroplastic events. 176 mRNA differential display, microarray, and biochemical studies have shown that short-term sleep deprivation is associated with an immediate 1) increase in levels of pCREB (the active form of this transcription factor); 2) increase in expression of BDNF; and 3) increase in expression of BDNF's receptor, TrkB.
As discussed previously, these are precisely the plasticity-related molecules whose expression is increased by chronic antidepressant treatment. In an extension of the gene expression studies, Cirelli and Tononi 176 hypothesized that a key factor responsible for the induction of the plasticity genes might be the level of activity of the neuromodulatory noradrenergic and serotonergic systems. Both of these systems project diffusely to most of the brain, where they regulate gene expression, and are only quiescent during rapid eye movement (REM) sleep.
During normal sleep, the noradrenergic system, represented by the locus ceuruleus (LC), is quiescent during REM sleep. During sleep deprivation, the noradrenergic system is activated at a time when it is normally quiet. The activity of the noradrenergic system in a different postsynaptic environment than normal may be the key factor in inducing physiological changes that result in mood elevation in depressed patients. One possible effect of an active noradrenergic system during a time when it is normally quiescent is an effect on gene expression. For example, the CREB-BDNF genes, which are known to be involved with neuroplasticity, may increase their expression levels in response. Increases in the expression of these genes have been shown to be downstream effects of antidepressants. Thus, a more rapid increase in their expression by manipulations of the noradrenergic system may underlie the rapid antidepressant response to sleep deprivation.
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Lithium and glycogen synthase kinase-3
The relevance of glycogen synthase kinase-3 (GSK-3) to the pathophysiology and treatment of mood disorders became apparent following the seminal observation that lithium directly inhibits this enzyme. 178, 179 Recent animal behavioral data have shown that manipulation of the GSK-3 signaling cascade produces both antimanic and antidepressant effects in pharmacologic and genetic models of depression and mania. 180 GSK-3, a component of many signaling pathways with multiple cellular targets 181 ( see FIG. 4 ) regulates multiple cellular processes such as glycogen synthesis, gene transcription, events related to synaptic plasticity, apoptosis, and the circadian cycle. 180, 182 In addition to lithium, serotonin and catecholamines, as well as a variety of other treatments known to have effects on mood including valproate, lamotrigine, antidepressants, antipsychotics, gonadal steroids, amphetamines, and electroconvulsive seizures, modulate GSK-3 either directly or indirectly within key areas of the brain implicated in BD. Thus, GSK-3 is situated at a nexus of multiple neurotransmitter and signaling cascades as well as neuroanatomic circuits putatively involved in BD.
GSK-3 is a major regulator of apoptosis and cellular plasticity/resilience. Generally, increased activity of GSK-3 is proapoptotic, whereas inhibition of GSK-3 attenuates or prevents apoptosis. 180, 181 Preclinical studies using animal models of Alzheimer's disease have shown that GSK-3 inhibition had beneficial effects on the ␤-amyloid and hyperphosphorylated tau cascades implicated in Alzheimer's disease. 183 Emerging data suggest that BD is associated with cell loss/atrophy, and there are now considerable data demonstrating that lithium exerts neuroprotective effects; these effects are believed to be mediated in large part by inhibition of GSK-3 and upregulation of Bcl-2.
184,185 Administration of dexamethasone has been shown in osteoblast cultures to oppose the downstream effects of GSK-3 inhibition on ␤-catenin and TCF/LEF-mediated transcription. 186, 187 If this finding holds true in the brain, it would represent an interesting relationship between the HPA axis and ␤-catenin/GSK-3.
As described above, abnormal energy metabolism in the LTC and LCSPT circuits has been noted in those with mood disorders. The central role played by GSK-3 in the insulin/IGF-I signaling pathway may offer a potential pathophysiological mechanism as well as a possible treatment target for abnormal cellular metabolism in affective illness.
Given their potential therapeutic effects in mood disorders as well as Alzheimer's disease and other neurodegenerative disorders, novel CNS-penetrant GSK-3 inhibitors are actively being developed by many pharmaceutical companies. 188 -190 Examples are summarized in Table 2 . Inositol monophosphatases may represent another important target for lithium's actions; however, at this point, there are no selective CNS-penetrant IMPases available for human use.
Valproate, histone deacetylase, and epigenetic regulation of neuroprotection
Valproate, a mainstay of mood stabilization treatment in BD, has recently been shown to be an inhibitor of histone deacetylase (HDAC). Acetylation of histones, by decreasing their affinity for DNA, is a significant epigenetic regulator of gene expression. It is possible that the therapeutic effects of valproate may in part be related to this important epigenetic mechanism. In support of this, valproate and several other HDAC inhibitors have shown neuroprotective effects in animal models of cerebral ischemia, 190, 191 Parkinson's disease, 192 and Huntington's disease. 193, 194 Weaver and associates 195 demonstrated in rat pups that behaviorally programmed, persistent epigenomic alterations of a glucocorticoid receptor gene promoter in the hippocampus induced by certain styles of maternal behavior could be reversed by central infusion of an HDAC inhibitor. Tremolizzo and colleagues 196 found that hypermethylation of the reelin promoter and subsequent decrease of reelin expression, which have been suggested by recent studies to be present in BD and schizophrenia patients, were prevented by valproate in doses inhibitory to HDACs. Thus, HDAC inhibitors represent a class of agents that may be available for clinical trials in mood disorders (see Table  2 ) as well as a theoretical model by which other agents that target epigenetic regulation mechanisms potentially involved in mood disorder pathogenesis may be pursued.
Protein kinase C signaling cascade: a shared biochemical target for the actions of chronic lithium and valproate
Lithium and valproate share similar effects on the protein kinase C (PKC) signaling cascade that are likely relevant to their antimanic profile. 197 PKC, a group of calcium and phospholipid-dependent enzymes, plays a pivotal role in cell signaling systems, plasticity, and long-term alterations in gene expression. A considerable amount of biochemical data, including evidence of changes in PKC and its substrates in bipolar patients and in PKC signaling pathways after treatment with lithium or valproate, 197 supports the potential involvement of PKC in the pathophysiology and treatment of BD.
Recently, Birnbaum and associates 198 demonstrated that excessive activation of PKC (including by stress)
FIG. 4.
Glutamatergic system. This figure depicts the various regulatory processes involved in glutamatergic neurotransmission. Once released from the presynaptic terminal, glutamate is able to bind to numerous excitatory amino acid (EAA) receptors, including both ionotropic (e.g., NMDA, AMPA) and metabotropic receptors. Glutamate has its action terminated in the synapse by reuptake mechanisms using distinct GLU transporters (GLUTs), which exist not only on presynaptic nerve terminals, but also on astrocytes. Indeed, current data suggest that astrocytic Glu uptake may be more important for clearing excess Glu, raising the possibility that astrocytic loss (as has been documented in mood disorders) may contribute to deleterious GLU signaling. It is now known that there are a number of important intracellular proteins that are able to alter the function of glutamate receptors (see diagram). Also, growth factors like GDNF and S100␤, secreted from glia, have been demonstrated to exert a tremendous influence on glutamatergic neurons and synapse formation. 5-HT 1A receptors, noted to be regulated by antidepressant agents, modulate the release of S100␤. Adapted with permission from Cooper et al., , Manji et al., 2003a dramatically impaired the cognitive functions of the prefrontal cortex, whereas inhibition of PKC (including indirectly with mood stabilizers) preserved cognitive function. Pharmacological inhibition of PKC results in many behavioral changes similar to the ones induced by mood stabilizers including attenuation of hyperactivity, risktaking behavior and hedonic drive (Einat and Manji, submitted) . 199 Psychostimulants, which are capable of triggering manic episodes in susceptible individuals and induce manic-like behaviors in rodents, are known to activate PKC. These data suggest that PKC modulation plays a critical role in the treatment of mania.
Based on these findings, a preliminary study suggested that the PKC inhibitor tamoxifen has antimanic properties. 200 Larger double-blind placebo-controlled studies of tamoxifen are currently in progress. Selective PKC inhibitors, currently in late stage clinical trials to treat diabetic complications, 182 have potential utility in the treatment of BD (see Table 2 ).
Thyroid hormone: neurotrophic effects in critical affective circuits
Significant evidence suggests a relationship of thyroid hormone with affective disorders. 201 The clinical efficacy of adjunctive thyroxine (T4) or triiodothyronine (T3) in the treatment of refractory unipolar and bipolar mood disorders has been fairly well established. 202 Cole et al. 203 observed in patients with bipolar depression that lower pretreatment thyroid activity (albeit within the normal range) predicted a worse response to treatment. Frye et al. 204 noted an inverse association between serum free T4 levels and increased mood instability and depression among bipolar patients maintained on lithium.
Mechanisms by which thyroid hormone may exert its thymoleptic effects are not clearly elucidated. Most research related to this question has been focused on the noradrenergic and serotonergic systems. 205, 206 More recently, evidence has emerged that thyroid hormone has neurotrophic effects. T3 exerts its actions through bind- ing to thyroid hormone receptors located in the nucleus. These receptors have been reported to be particularly dense in key limbic regions such as the amygdala and hippocampus. 207, 208 The T3-receptor complex acts to increase expression of target genes, which are known to include neurotrophins and their receptors, transcription factors, and proteins involved in intracellular signaling. As reviewed in Manji and colleagues, 134 thyroid activity in rats influences the balance between G␣i and G␣s (the G proteins that inhibit and stimulate, respectively, adenylyl cyclase) in a variety of tissues, including the brain. Specifically, hypothyroid states have been shown to decrease cAMP signaling, whereas thyroid supplementation increases it and thereby exerts neurotrophic effects via CREB activation.
Given the evidence for thyroid hormone involvement in mood disorders and their treatment, it is surprising that few functional imaging studies have examined these relationships. Marangell et al. 209 reported an inverse relationship of peripheral TSH levels to brain activity. More recently, Bauer and colleagues 210 used fluorodeoxyglucose PET to examine the effects of adjunctive supraphysiological doses of levothyroxine on cerebral glucose metabolism in euthyroid women with bipolar depression. Pretreatment scans of these women revealed abnormal glucose metabolism compared to healthy controls. After 7 weeks of levothyroxine treatment and significant clinical improvement, subsequent scans showed widespread metabolic decreases in limbic and subcortical areas including the amygdala, hippocampus, caudate, ventral striatum, thalamus, and cerebellar vermis, suggesting a link between the therapeutic effects of levothyroxine and modulation of regions implicated in key affective neuronal circuits.
3) EXPERIMENTAL THERAPEUTICS TARGETING MEDIATORS OF CELLULAR RESILIENCE AND PLASTICITY
We now turn to a discussion of several other plasticity-enhancing strategies currently under investigation in mood disorders (see FIG . 5 and Table 2 for an overview).
The HPA axis as a target for the development of novel therapeutics
Drugs that have been tested that modulate the HPA axis include inhibitors of glucocorticoid synthesis, glucocorticoid receptor (GR) antagonists (e.g., RU486), hydrocortisone to downregulate the HPA axis (as a proofof-concept study), CRH1 antagonists (e.g., antalarmin), and dehydroepiandrosterone (reviewed in Quiroz et al., 2004 135 ). Examples are provided in Table 2 . Some of these drugs are being investigated for proof of concept, and it is expected that modified and improved medications would lack some of the limiting side effects observed with these compounds.
Glutamatergic strategies
Because of the role of glutamate in neuronal plasticity, and independently of interactions with the HPA axis, modulation of the glutamatergic system is being investigated as a mood regulating strategy in a number of ongoing clinical studies by our group and others. 211, 212 Glutamate exerts its action at the presynaptic and postsynaptic level through the stimulation of specific ionotropic and metabotropic receptors ( see FIG. 4 ). Therapeutics targeting these receptors and/or the presynaptic release of glutamate may result in modulation of the glutamatergic system and ultimately to circuitrysparing and mood-enhancing effects.
Inhibition of glutamate release. Efficacy of the anticonvulsant lamotrigine, 213 now FDA-approved for the maintenance treatment of adults with BD, provides clinical evidence that modulation of glutamatergic neurotransmission may be important in the treatment of mood disorders. 214 Although lamotrigine has multiple cellular effects, inhibition of excessive presynaptic glutamate release appears to be important to its mechanism of action. [215] [216] [217] Supporting this idea, there is now preliminary evidence that riluzole, another drug that inhibits the release of glutamate, also has antidepressant properties both in MDD and BD. 218, 219 Riluzole, approved by the FDA for the treatment of amyotrophic lateral sclerosis, exhibits neuroprotective properties in animal models of Parkinson's disease, NMDA receptor hypofunction neurotoxicity, ischemia and traumatic CNS injury. 212, 213 NMDA receptor antagonism. The NMDA receptor complex may be involved in the pathophysiology and treatment of mood disorders. NMDA receptor antagonists such as MK-801 and AP-7 have been shown to have antidepressant effects comparable to the tricyclic antidepressants in various animal models of depression. 212 MK-801 increases neurogenesis in the brains of rats. 220 A recently completed double-blind, placebo-controlled trial of the low-to moderate-affinity NMDA antagonist memantine in patients with MDD was negative. 221 There is evidence that a single dose of the high-affinity NMDA receptor antagonist, ketamine, has efficacy in the treatment of depression. 222, 223 Studies in progress are examining the possible therapeutic value of other NMDA receptor antagonists.
AMPA receptors. AMPA receptors, a subfamily of ionotropic glutamate receptors that mediate the fast component of excitatory neurotransmission, are involved in learning and memory. Ampakines and several other classes of AMPA receptor potentiators (ARPs) allosterically modulate AMPA receptors to slow the rate of receptor desensitization and/or deactivation in the presence of an agonist (e.g., glutamate and AMPA). 224, 225 Various ARPs have demonstrated antidepressant properties in a number of preclinical models of depression 226, 227 (see Table 2 ). They have been associated with enhanced neurogenesis 228 and increased expression of neurotrophic factors such as BDNF. 229, 230 The AMPAkine Ampalex exhibited more rapid effect (during the first week of treatment) than fluoxetine (after 2 weeks).
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Metabotropic glutamate receptors. In addition to the ionotropic receptors, G-protein-coupled metabotropic glutamate receptors (mGluR) mediate slower modulatory actions of glutamate on neurotransmitter release and cell excitability. Group I mGluR antagonists have potential therapeutic effects in CNS disorders involving excess excitatory neurotransmission (e.g., epilepsy and ischemia). 232 Preclinical studies suggest that mGlu 2/3 agonists have antianxiety, antipsychotic, and neuroprotective properties. [233] [234] [235] Selective activation/antagonism of various mGluRs can lead to either anxiolytic-and/or antidepressant-like effects, 236 -239 and specific interactions of each receptor subtype are an intensive area of investigation. 212 The complex glutamate signaling system provides great potential for novel, plasticity-enhancing therapeutic strategies in mood disorders and other CNS disorders.
Strategies to enhance neurotrophic factor signaling and neuroprotective effects
One approach to enhance the activity of CREB is by inhibiting phosphodiesterase (PDE), the enzymes responsible for the breakdown of cAMP. Several previous studies have suggested that rolipram, a specific inhibitor of the high-affinity cAMP PDE4, may have antidepressant efficacy in depressed patients. 134 Although studies of rolipram have not been pursued further due to doselimiting side effects, these data suggest that PDE4A and PDE4B may be worthwhile targets for development of novel antidepressant agents, either as monotherapy or in conjunction with agents that augment intrasynaptic monoamine levels due to potential synergistic effects on the cAMP cascade. Multiple strategies are being investigated to develop agents to regulate the activity of growth factors, MAP kinase cascades, and the Bcl-2 family of proteins (see FIG. 3 and Table 2 ). The neuroprotective Bcl-2 is a key regulator of mitochondrial function, and there is a growing appreciation of the critical functions of mitochondria in regulating integrated CNS function. For example, increasing evidence suggests that mitochondrial Ca 2ϩ sequestration plays a key role in modulating the tone of synaptic plasticity in a variety of neuronal circuits. Lithium's ability to robustly upregulate Bcl-2 may is likely involved in its antidepressant potentiating effects. Pramipexole, shown to exert antidepressant effects in a double-blind placebo-controlled trial in patients with bipolar II depression, 110 upregulates Bcl-2 in several brain regions. Although the dopamine agonistic effects of pramipexole may also contribute to its antidepressant effects, its neurotrophic effects suggest broader utility as an antidepressant potentiator.
CONCLUSIONS
Despite currently available treatments, MDD and BD remain leading causes of disability worldwide, illustrating the need for novel therapeutic strategies in addressing these illnesses.
Through functional brain imaging studies, affective circuits have been identified that mediate the behavioral, cognitive, and somatic manifestations of mood disorders. Key areas of these circuits include the amygdala and related limbic structures, orbital and medial prefrontal cortex, anterior cingulate, medial thalamus, and related regions of the basal ganglia. Imbalance within these circuits, rather than an increase or decrease in any single region of the circuit, seems to predispose to and mediate the expression of affective illness.
Factors that impact neuroplasticity and cellular resilience, such as altered HPA axis and glutamate neurotransmission and impaired neurotrophic/neuroprotective signaling, appear to underlie disturbances in these key affective circuits. Treatments that more directly restore balance to these circuits may prove more effective in those with mood disorders, particularly in refractory cases. Promising experimental approaches include pharmacological restoration of these circuits using neuroplasticity-enhancing strategies such as modulation of altered HPA axis or glutamatergic activity and manipulation of key neurotrophic/neuroprotective signaling cascades and, possibly, direct stimulation of these circuits via instrumentation (e.g., deep brain stimulation, magnetic stimulation, or vagus nerve stimulation). As these novel treatment strategies are developed further, functional imaging studies of these interventions (including molecular imaging techniques as well as circuit-based approaches) are likely to yield greater understanding into the mechanisms of response for these treatments and the underlying neurobiology of mood disorders, leading ultimately to more refined and specifically targeted therapies.
